HER2 and HER3-mediated PI3K/AKT signaling was also reported to increase resistance for several chemotherapeutic agents, including 5-fluorouracil, paclitaxel, camptothecin, and etoposide in breast cancer cells [114]. Here, ERBB2 is linked to breast carcinoma.